Syros Pharmaceuticals, Inc.

Thank you for standing by. Welcome to the Q3 2021 Heroes Pharmaceuticals, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would like to hand the conference over to your speaker today, Courtney Solberg with T-Rose. Please go ahead.

Thank you. This morning we issued a press release with our third quarter 2021 financial results, along with anticipated future milestones and recent accomplishments. This release is available on the Investors and Media section of Cirrus's website at www.cirrus.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, Kristen Stevens, our Chief Development Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Dr. Eric Olson, our Chief Scientific Officer, and Conley Chee, our Chief Commercial Officer, are also on the call and will be available for Q&A. Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors including those set forth in the risk factors section of our annual report on Form 10-K, our quarterly report on Form 10-Q that were filed this morning, and any other filings that we make with the SEC in the future. In particular, the extent to which the COVID-19 outbreak continues to impact our operations and those of the third parties on which we rely will depend on future developments which are highly uncertain and cannot be predicted with confidence. Any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. I would now like to turn the call over to Nancy.

Thank you, Courtney. The third quarter of 2021 was extremely productive for Cirrus as we continue to execute towards our three strategic priorities that we laid out in the beginning of the year. We are leveraging our leadership and expertise to build a synergistic portfolio where success in one program can inform and benefit efforts in another. We believe we are well on our way towards achieving our goal of becoming a fully integrated biopharmaceutical company that has the potential to provide profound benefit for patients with cancer and monogenic diseases. This quarter, we made two new strategic hires, adding additional strength to our experienced leadership team as we prepare for two expected NDAs in 2024. In September, we appointed Conley Chee as our first Chief Commercial Officer, bringing 20 years of pharmaceutical sales leadership, marketing, and strategy experience. In October, Jason Haas joined Cirrus as our new chief financial officer, bringing more than 25 years of healthcare investment banking and corporate finance experience. We are excited to have them on board. Importantly, as David and Kristen will review shortly, we made tremendous progress across both our hematology and CDK7 portfolios. In September, we dosed the first patient in our Select AML-1 Phase II trial of Tamiberitone and Rara-positive unfit AML patients, and the first patient in our dose confirmation study of SY-2101 in newly diagnosed APL patients. These milestones showcase our team's commitment to quickly advance medicines that have the potential to offer new standards of care for patients with hematologic cancers. Furthermore, at ESMO, we presented encouraging Phase I data for SY5609, our highly selective and potent CDK7 inhibitor, which showed single-agent clinical activity at tolerable doses. We believe 5609 has the ability to attack cancer in multiple ways and could therefore become a transformative targeted therapy. With that, I'd like to turn the call over to David, who will review our progress across our hematology and CDK inhibitor programs in more detail.